All Episodes
RhAPPcast — 209 episodes
Journal Club Review: Deucravacitinib in Active PsA: 52-Week Efficacy and Safety From POETYK PsA-2
RhAPPcast: Cracking the Code: A Rheum Derm Neuro Multispecialty Case Approach to Myositis
RhAPPcast: Beyond the Joint: Uncontrolled Gout as a Systemic Disease
Journal Club Review: TOGETHER-PsA Trial
FAQ: How Do Clinical Manifestations and Histopathologic Features Vary Across Myositis Subtypes?
FAQ: What Are the Key Unmet Needs in the Treatment of Idiopathic Inflammatory Myopathies?
RhAPPcast: Switch, Don’t Cycle: Interpreting the SELECT-SWITCH Trial and What It Means for RA Care
RhAPPcast: Treat-to-Target in SLE: DORIS Remission Real in Practice
RhAPPcast: Pharmacists in Rheumatology
RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 3
RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 2
RhAPPcast: EULAR Osteoporosis RhAPP Up: Part 1
RhAPPcast: EULAR PsA RhAPP Up: Part 3
RhAPPcast: EULAR PsA RhAPP Up: Part 2
RhAPPcast: EULAR PsA RhAPP UP: Part 1
RhAPPcast: EULAR ILD RhAPP Up: Part 3
RhAPPcast: EULAR ILD RhAPP Up: Part 2
RhAPPcast: EULAR ILD RhAPP UP: Part 1
RhAPPcast: TYK2 Inhibition in PsA, Sjögren’s and SLE: What APPs Need to Know as Future Uses Emerge
Journal Club Review: SURMOUNT-5
Medication Review: Deucravacitinib Dosing, Administration, DDIs, & Safety in Clinical Practice
Podcast: Weight, Wellness, and PsA: Empowering Conversations & Action in the Rheumatology Clinic
FAQ: TYK2/STAT Signaling: The Immunologic Rationale for TYK2 Therapy in SLE & Sjögren’s Disease
RhAPPcast: From Prescription to Possession: Understanding Medicare Access & Cap and Smooth
FAQ: What Is Minimal Disease Activity in PsA and How Does Deucravacitinib Perform at 52 Weeks?
FAQ: What Guideline Recommendations Exist Pertaining to Managing obesity in Patients With PsA?
RhAPPcast: Identification and Diagnosis of XLH: A Story of Family History
Medication Review: What Is the Safety Profile of Tirzepatide?
Medication Review: Tirzepatide Starting Dose & Titration for Optimal Outcomes
Journal Club Review: SOLSTICE Publication
FAQ: How Can HPP Be Misdiagnosed in Rheumatology and What Are Common Diagnostic Pitfalls?
Medication Review: Describe The Mechanism of Action of Tirzepatide
Journal Club Review: APEX Publication
RhAPPcast: Diagnostic Crossroads: Clues, Pitfalls, and the Journey to an HPP Diagnosis
Journal Club Review: The Challenge of Hypophosphatasia Diagnosis in Adults
FAQ: How Does Weight Reduction Impact PsA Outcomes?
FAQ: What Are the Neuromuscular and Functional Burdens of Living With HPP?
RhAPPcast: IVIG Unpacked
Journal Club Review: DISCOVER-2 Severe PsA Publication
FAQ: How Does Obesity Affect PsA Outcomes?
FAQ: What Skeletal and Dental Manifestations Might Indicate HPP?
RhAPPcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC
RhAPPcast: Upadacitinib in GCA: Interpreting the 2-Year SELECT-GCA Results
FAQ: What is the Importance of MRI in Assessing Axial Disease Manifestations in PsA?
FAQ: How Does Obesity Impact the Immune System?
FAQ: What Role Does Power Doppler Ultrasound Play in Detecting Subclinical Inflammation/Enthesitis?
RhAPPcast: Unpacking the Genetics: Low ALP
FAQ: What Is the Efficacy of Switching MOA to Guselkumab After Inadequate Response to a single TNFi?
Podcast: Inflammation Intersection: A Rheum-Gi Dialogue
RhAPPcast: Protecting Joints: Inhibiting Structural Damage in PsA With Guselkumab
FAQ: How Can Clinicians Best Approach Talking to Patients With PsA About Weight Management?
Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?
Medication Review: Anti-Drug Antibody Development With Guselkumab in Psoriasis, PsA & IBD
FAQ: What Role Does Tissue-Nonspecific Alkaline Phosphatase (TNSALP) Play in HPP?
Medication Review: Laboratory Monitoring for Guselkumab in Psoriasis, PsA, and IBD
Podcast: Inflammation Amplified: Understanding the PsA—Obesity Connection
Medication Review: Safety and Efficacy of Guselkumab in Crohn’s Disease and Ulcerative Colitis
Across The Rheum Podcast: Part 3 - Clinical Utility and Positioning of IL-23 Agents
Podcast: Under the Surface: Exploring the HPP Diagnosis in Adulthood
FAQ: Screening Tools APPs Use to Identify PsA, SpA, or IBD and Refer Early
FAQ: What Validated Screening Tools Identify PsA/SpA or IBD for Rheumatology or GI Referral?
Across The Rheum Podcast: Part 2 - Currently Available IL-23 Agents
Journal Club: HPP Diagnosis—Current State of the Art & Proposed Criteria for Children and Adults
Med Review: What is the Safety and Efficacy Profile of Guselkumab in Juvenile Psoriatic Arthritis?
Across The Rheum Podcast: Part 1: Immunology of IL-23
RhAPPcast: Born with Burden: Understanding the Pediatric Presentation of HPP
RhAPPcast: Unpacking the Differences: IL-23 Inhibitors in Focus
FAQ: What is Hypophosphatasia and How Does It Present Across the Lifespan?
Journal Club: Guselkumab Binds To CD64+ IL-23–Producing Myeloid Cells to Neutralize IL-23 Signals
FAQ: How Is Hypophosphatasia Diagnosed and What Are the Key Laboratory Markers?
What Is the Correlation of CD64 and IL-23 Expression in Inflamed Joint, Skin, and Gut Tissue?
FAQ: What is the Normal Role of CD64 in Innate and Adaptive Immunity?
Podcast: A Tale of Two Pediatric APPs
Medication Review: Describe the Dual Mechanism of Action of Guselkumab
FAQ: Why is the mvdH-S Score Used Most Often in PsA Trials?
FAQ: How Does The Design of APEX Differ From DISCOVER-2 To Enrich For Structural Damage?
The Conversation That Matters: Talking to Patients About Obesity and IMIDs
From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs
The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs
Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts
Live from RhAPP National: ILD & PH-ILD at the Rheum–Pulm Crossroads
RhAPPcast: ANCA-Associated Vasculitis: Insights From the RhAPP National Conference
FAQ: What is the clinical significance of structural damage in PsA?
Medication Review: Evidence for Guselkumab in Preventing Structural Damage Progression
RhAPPcast: Beyond Dryness: Key Takeaways from the Sjögren’s Symposium at RhAPP 2025
FAQ: What is the Effect of Guselkumab on Structural Damage in PsA?
FAQ: What is the Inflation Reduction Act & How Does It Impact Affordability of Biologic Therapies?
RhAPPcast: Unmasking XLH: Misdiagnosed and Misunderstood
RhAPPcast: Refractory PMR: When Steroids Aren’t Enough – Unmet Needs in Treatment
RhAPPcast: The Safety Conversation: Upadacitinib in the Treatment of GCA
Medication Review: What is the safety profile of sarilumab in PMR & RA?
RhAPPcast: Expanding the Arsenal: JAK Inhibitors in the Evolving GCA Landscape
Medication Review: How is Sarilumab Dosed & Administered for the Treatment of PMR & RA?
Medication Review: Key Patient Education When Starting Sarilumab for PMR or RA
RhAPPcast: Inside the Evidence: A Deep Dive into the SELECT-GCA Study
RhAPPcast: Laying the Foundation: Historical Approaches to GCA Treatment
FAQ: What is the Role of Sarilumab in Managing PMR?
Journal Club: Comparative Effectiveness of Sarilumab vs. Methotrexate as a Corticosteroid-Sparing Agent in Patients with Polymyalgia Rheumatica
FAQ: Choosing Between Steroid-Sparing Agents in PMR Treatment
Medication Review: Leflunomide Medication Review
RhAPPcast: Spotting the Signs: Recognizing and Diagnosing Giant Cell Arteritis
RhAPPcast: Foundations of PMR: Diagnosis, First-Line Therapy, and Tapering Strategies
Journal Club Review: Sarilumab for Relapse of Polymyalgia Rheumatica During Glucocorticoid Taper
FAQ: Steroid-Sparing Agent Consideration in PMR Management & What Options Are Available?
FAQ: What Are the Most Recent Treatment Guidelines for PMR, and What Are the Key Clinical Takeaways?
Medication Review: What is the Mechanism of Action of Methotrexate?
Journal Club Review: A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis
RhAPPcast: Understanding the TYK2/STAT Signaling Pathway in PsA: Clinical Implications and Beyond
Medication Review: Hydroxychloroquine Medication Review
FAQ: How Does the Selectivity of TYK2 and JAK Enzyme Inhibition Influence Their Safety Profiles
FAQ: According to the New 2024 ACR Guidelines for Lupus Nephritis, How Do You Monitor LN?
FAQ: Can You Recapture Response to IL-17i Therapy After Interruption or Discontinuation in Therapy?
FAQ: Steroid Tapering in Lupus Nephritis: Insights from the 2024 ACR Guidelines
Medication Review: What Is the Safety Profile of Deucravacitinib in PsO and PsA?
Journal Club Review: Voclosporin in Lupus Nephritis: New Insights on Efficacy & Safety from Clinical Trials
Medication Review: What is the Mechanism of Action of Deucravacitinib?
RhAPPcast: Practical Application: Integrating the New ACR LN Guidelines
Medication Review: What is the Real World Evidence of Guslekumab in PsA
FAQ: TYK2/STAT Pathway & Why TYK2 Therapy Works for Psoriasis and Psoriatic Arthritis
RhAPPcast: Decoding IL-17: Comparing and Contrasting IL-17A and IL-17F Inhibition
Medication Review: What Are the Clinically Meaningful Differences Between Voclosporin and Other Calcineurin Inhibitors?
RhAPPcast: ACR Psoriatic Arthritis RhAPPUp Part 3
RhAPPcast: ACR Psoriatic Arthritis RhAPPUp Part 2
RhAPPcast: ACR Psoriatic Arthritis RhAPPUP Part 1
RhAPPcast: The Relative Persistency and Effectiveness of Guselkumab in the Real-World
Medication Review: What is the safety profile of voclosporin and how should it be monitored?
Journal Club Review: Evaluating the Efficacy of Biologic With and Without Methotrexate
Journal Club Review: Voclosporin for Lupus Nephritis: Efficacy & Safety Insights from AURORA 1 & 2 Trials
Medication Review: Voclosporin Dosing, Administration, Adjustments & Interactions
Medication Review: What is the Efficacy of Guselkumab Across the GRAPPA Domains
FAQ: Are IL-17 Inhibitors Efficacious in Treating the Nail-DIP Complex in PsA?
FAQ: What Are CNIs? Treating Lupus Nephritis with the Latest ACR Guidelines
RhAPPcast: Elevating Care in LN: What the New ACR Guidelines Mean for Patients & How APPs can Apply Them
FAQ: How do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy
Journal Club Review: Ixekizumab vs. Guselkumab in Plaque Psoriasis (12-Week Trial Results)
Medication Review: What is Voclosporin and How Does it Work?
FAQ: According to the New 2024 ACR Guidelines for LN, What Are the Treatment Goals For Patients With LN?
Journal Club Review: Long-Term Safety of Guselkumab in Patients with Psoriatic Disease
RhAPPcast: Navigating Leflunomide Use in Pregnant Patients with Sjögren’s Syndrome
FAQ: According to the New 2024 ACR Guidelines, How Do You Treat LN?
FAQ: How Do You Interpret cDAPSA/DAPSA and MDA?
FAQ: How Do You Explain The Timing of Ixekizumab's Clinical Efficacy to Patients?
FAQ: 2024 ACR Guidelines: Screening & Diagnosing Lupus Nephritis in SLE Patients
RhAPPcast: LN Updates Unpacked: Insights on New ACR Guidelines
FAQ: How is Lupus Nephritis Defined?
FAQ: How Does Real-World Evidence Differ From Randomized Controlled Trials
FAQ: How Long Has It Been Since the Last ACR LN Guideline Updates, and Why Is This Significant?
Journal Club Review: Effectiveness of Methotrexate and Leflunomide as Corticoid-Sparing Drugs
RhAPPcast :The Clinical Utility of Guselkumab in Axial PsA
Journal Club Review: Efficacy & Safety of Ixekizumab ± Methotrexate in PsA (52-Week SPIRIT-H2H)
FAQ: How Do You Interpret Radiographic Progression Using Modified-vdHS or mTSS?
Medication Review: What Is the Efficacy of Ixekizumab Across the GRAPPA and EULAR Domains?
Medication Review: What Is the Safety Profile of Guselkumab in PsO and PsA?
FAQ: How Does Axial PsA Differ From AS Clinically, Genetically, and Radiographically?
Journal Club Review: 6-Month Guselkumab Effectiveness in PsA (Real-World CorEvitas Data)
RhAPPcast: Navigating the Complexities: IL-17 Inhibitors and IBD Risk
FAQ: Why is Binding CD64+ Important When Discussing IL23 Directed Therapy
Journal Club Review: Upadacitinib Safety & Efficacy in Pediatric JIA (Phase-1 Interim Data)
RhAPPcast: Lost Time: The Impact of Delaying Optimal Therapy in RA & SpA Patients Without Disease Control
Journal Club Review: 5-Year Data on Switching Upadacitinib & Adalimumab in RA
FAQ: Definition of Remission in Rheumatoid Arthritis & Likelihood with Advanced Therapies
Medication Review: How is Guselkumab dosed in PsO, PsA, and IBD
RhAPPcast: Navigating Remission in Rheumatoid Arthritis: Approaches, Advances, Impact, and Insights
FAQ: Variability in JAK Inhibition Specificity & Its Clinical Implications
RhAPPcast: CD64+ Binding Description, Relevance, and Potential Clinical Implications
FAQ: What Is the Difference Between Biosimilars and Generics?
FAQ: What Is the ORAL Surveillance Study and How Can It Be Applied to Clinical Practice?
FAQ: What is the Safety Profile of Ixekizumab in PsA and axSpa
Medication Review: What Is the Safety Profile of Upadacitinib Across Indications?
FAQ: Provide Immunologic Rationale For IL23 Directed Therapy in PsA, PsO, and IBD.
RhAPPcast: Biosimilars and The Patient Perspective
Medication Review: How Is Upadacitinib Dosed Across Rheumatologic Indications?
FAQ: Provide Immunologic Rationale for JAK-Directed Therapy in Rheumatic Disease
Medication Review: Describe the Mechanism of Action of Upadacitinib
FAQ: Provide Immunologic Rationale For IL17-Directed Therapy in PsA, AS, and nr-axSpA
FAQ: Describe the IL17-Induced Inflammatory Cascade
FAQ: Describe JAK-STAT Signaling in Inflammation
FAQ: What Does It Mean for a Biosimilar to Be Interchangeable and Why Is That Important?
Journal Club Review: Long-Term Efficacy and Safety of Guselkumab
Medication Review: What is Non-Responder Imputation and How is it Utilized in Clinical Trials
RhAPPcast: Biosimilars Unveiled - Empowering APPs for Better Patient Conversations
Medication Review: Describe The Mechanism of Action of Ixekizumab
FAQ: What is The Role of IL23/IL17 Axis in Rheumatic Disease
RhAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD
The 2024 RhAPP National Conference in Nashville, TN
FAQ: Describe The IL23/IL17 Axis
Journal Club Review: Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23
Medication Review: Describing the Mechanism of Action of Guselkumab
FAQ: Define, compare, and contrast humoral and cell-mediated immunity.
RhAPPcast Spotlight: Clinical Cornerstones with Lindsay Tom, PA-C
RhAPPcast Spotlight: Clinical Cornerstones with Cayla Alexander, DNP, ARNP
Breathing New Life: HRCT and PFTs in ILD with Corinne Young of APAPP
Spotlight: Clinical Cornerstones, Mary Elliott, PA-C
Leading the Way: Dr. John Cush on Rheumatology Leadership
Discussing Biosimilars With Patients
The Nocebo Effect
Voices for Change: Madelaine Feldman, MD of CSRO on Advocacy in Rheumatology
The Practical Use of Biosimilars in Gastroenterology APP Practice
The Practical Use of Biosimilars in Rheumatology APP Practice
The Benefits of Biosimilars
Managed Care and Biosimilars
Interchangeability & Switching of Biosimilars
Spotlight: Clinical Cornerstones, Daric Mueller, MS, PA-C
Biosimilar Extrapolation
The Difference Between Biosimilars & Generic Drugs
The Regulatory Pathway to Biosimilar Approval
Development of Biosimilars
From Idea to Impact: The RhAPP Origin Story
Biosimilars Series: What Are Biosimilars?